Lundbeck Advances Migraine Portfolio with New Data on Eptinezumab and Bocunebart — H. Lundbeck A/S (The Lundbeck Foundation)

Event summary

Lundbeck will present five migraine-related data sets at EAN 2026, including new analyses of eptinezumab and Phase IIb PROCEED primary data for bocunebart.
Eptinezumab data explore patient-centered outcomes beyond traditional endpoints, such as acute medication use, psychological well-being, and workplace productivity.
Bocunebart targets the PACAP pathway, a novel approach distinct from anti-CGRP therapies, aiming to address treatment failures in migraine prevention.
The presentations underscore Lundbeck's dual focus on optimizing current treatments and advancing future therapeutic approaches for unmet needs in migraine.

The big picture

Lundbeck's presentations at EAN 2026 highlight its strategic push into migraine prevention, an area with significant unmet needs. The focus on patient-centered outcomes and novel mechanisms like PACAP inhibition reflects broader industry trends toward personalized neurology treatments. With eptinezumab already approved in multiple markets, the company is positioning itself to dominate a growing segment of the neurological disorder market.

What we're watching

Clinical Validation: Whether bocunebart's novel PACAP pathway inhibition can demonstrate superior efficacy in migraine prevention, particularly for treatment-resistant patients.
Regulatory Pathway: The pace at which Lundbeck advances bocunebart through Phase III trials and potential regulatory filings, given its investigational status.
Market Differentiation: How Lundbeck positions eptinezumab and bocunebart against existing anti-CGRP therapies to capture market share in the migraine prevention space.